Meeting
2021 ASCO Annual Meeting
Using the tumor microenvironment to identify predictors of immunotoxicity to checkpoint inhibitors.
Authors
William Alexander
University at Buffalo, Buffalo, NY
William Alexander , Kristopher Attwood , Kayla Catalfamo , Grace K. Dy , Saby George , Marc S. Ernstoff , Yara Abdou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Inflammatory Signatures
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2545)
DOI
10.1200/JCO.2021.39.15_suppl.2545
Abstract #
2545
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma.
First Author: Mark Chang
Poster
2024 ASCO Annual Meeting
Retrospective analysis of change in frequency of STK11 mutation in lung adenocarcinomas over a 10-year period.
First Author: Deevyashali Parekh
Poster
2023 ASCO Annual Meeting
Using machine learning to characterize lung cancer microenvironment and the development of a model to predict the presence of similar microenvironment in other cancers.
First Author: Ahmad Charifa
Poster
2023 ASCO Annual Meeting
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
First Author: Kristina Fanucci